As many of you may have seen, a recent BBC news report (February 2015) highlighted new research into how conventional hormone replacement therapy (HRT) can increase the risk of some ovarian cancers. Whilst the increased risk of breast cancer is well documented the impact on ovarian cancer has been debated for some years. The BBC reported, however, that “The University of Oxford research, in the Lancet, found an extra case for every 1000 women taking the drugs for five years from the age of 50” which as a leading cancer charity commented was a “modest increase on a relatively uncommon cancer.”
In light of this recent research we thought it may be of interest to share with you some other more positive research into the differences between conventional HRT and bio-identical HRT (BHRT). Whilst conventional HRT is given as a standard combination drug containing both estrogen and a progestin, BHRT is hormone therapy designed and tailored for each individual patient. Every person is unique when it comes to menopausal symptoms and hormone levels. BHRT recognises this and replaces hormonal deficiencies specifically to the individual.
Recent reports by Dr. Toledano of the Marion Gluck Clinic in London claim that whilst conventional HRT can increase the risk of some ovarian cancers there is no increased risk when using BHRT and that progesterone – which is given as part of the BHRT – can actually have a protective effect against ovarian cancer. (Dr. Toledano, Marion Gluck Clinic, March 2015)
More information and research into the benefits of Bio-identical HRT can be found on the Marion Gluck Clinic website – a leading specialist in the use of bio-identical hormones.